Kevin T Schwalbach1, Sylvia S Yong1, R Chad Wade2, Joseph Barney3. 1. University of Alabama at Birmingham, Department of Medicine, 1720 2nd Ave South, BDB 321, Birmingham, AL 35294-0012, United States. 2. University of Alabama at Birmingham Division of Pulmonary, Allergy and Critical Care Medicine, 1900 University Blvd., Tinsley Harrison Tower, Suite 422, Birmingham, AL 35294, United States. 3. University of Alabama at Birmingham Division of Pulmonary, Allergy and Critical Care Medicine, 1900 University Blvd., Tinsley Harrison Tower, Suite 422, Birmingham, AL 35294, United States. Electronic address: jbarney@uabmc.edu.
Abstract
AIM: To compare outcomes between Intraosseous (IO) and peripheral intravenous (PIV) injection during in-hospital cardiac arrest (IHCA) and examine its utility in individuals with obesity. METHODS: We performed a retrospective cohort analysis of adult, atraumatic IHCA at a single tertiary care center. Subjects were classified as either IO or PIV resuscitation. The primary outcome of interest was survival to hospital discharge. The secondary outcomes of interest were survival with favourable neurologic status, rates-of-ROSC (ROR) and time-to-ROSC (TTR). Subgroup analysis among patients with BMI ≥ 30 kg/m2 was performed. RESULTS: Complete data were available for 1852 subjects, 1039 of whom met eligibility criteria. A total of 832 were resuscitated via PIV route and 207 via IO route. Use of IO compared to PIV was associated with lower overall survival to hospital discharge (20.8% vs 28.4% p = 0.03), lower rates of survival with favourable neurologic status (18.4% vs 25.2% p = 0.04), lower ROR (72.2% vs 80.7%) and longer TTR (12:38 min vs 9:01 min). After multivariate adjustment there was no significant differences between IO and PIV in rates of survival to discharge (OR 0.71, 95% CI 0.47-1.06, p = 0.09) or rates of survival with favourable neurologic status (OR 0.74, 95% CI 0.49-1.13, p = 0.16). The ROR and TTR remained significantly worse in the IO group. Subgroup analysis of patients with BMI ≥ 30 kg/m2 identified no benefit or harm with use of IO compared to PIV. CONCLUSION: Intraosseous medication delivery is associated with inferior rates-of-ROSC and longer times-to-ROSC compared to PIV, but no differences in overall survival to hospital discharge or survival with favourable neurologic status during IHCA.
AIM: To compare outcomes between Intraosseous (IO) and peripheral intravenous (PIV) injection during in-hospital cardiac arrest (IHCA) and examine its utility in individuals with obesity. METHODS: We performed a retrospective cohort analysis of adult, atraumatic IHCA at a single tertiary care center. Subjects were classified as either IO or PIV resuscitation. The primary outcome of interest was survival to hospital discharge. The secondary outcomes of interest were survival with favourable neurologic status, rates-of-ROSC (ROR) and time-to-ROSC (TTR). Subgroup analysis among patients with BMI ≥ 30 kg/m2 was performed. RESULTS: Complete data were available for 1852 subjects, 1039 of whom met eligibility criteria. A total of 832 were resuscitated via PIV route and 207 via IO route. Use of IO compared to PIV was associated with lower overall survival to hospital discharge (20.8% vs 28.4% p = 0.03), lower rates of survival with favourable neurologic status (18.4% vs 25.2% p = 0.04), lower ROR (72.2% vs 80.7%) and longer TTR (12:38 min vs 9:01 min). After multivariate adjustment there was no significant differences between IO and PIV in rates of survival to discharge (OR 0.71, 95% CI 0.47-1.06, p = 0.09) or rates of survival with favourable neurologic status (OR 0.74, 95% CI 0.49-1.13, p = 0.16). The ROR and TTR remained significantly worse in the IO group. Subgroup analysis of patients with BMI ≥ 30 kg/m2 identified no benefit or harm with use of IO compared to PIV. CONCLUSION: Intraosseous medication delivery is associated with inferior rates-of-ROSC and longer times-to-ROSC compared to PIV, but no differences in overall survival to hospital discharge or survival with favourable neurologic status during IHCA.
Authors: Purav Mody; Siobhan P Brown; Peter J Kudenchuk; Paul S Chan; Rohan Khera; Colby Ayers; Ambarish Pandey; Karl B Kern; James A de Lemos; Mark S Link; Ahamed H Idris Journal: Resuscitation Date: 2018-11-01 Impact factor: 5.262
Authors: Stephen L Hoskins; Paulo do Nascimento; Rodrigo M Lima; Jonathan M Espana-Tenorio; George C Kramer Journal: Resuscitation Date: 2011-08-25 Impact factor: 5.262
Authors: Jerry P Nolan; Charles D Deakin; Chen Ji; Simon Gates; Andy Rosser; Ranjit Lall; Gavin D Perkins Journal: Intensive Care Med Date: 2020-01-30 Impact factor: 17.440
Authors: Asger Granfeldt; Suzanne R Avis; Peter Carøe Lind; Mathias J Holmberg; Monica Kleinman; Ian Maconochie; Cindy H Hsu; Maria Fernanda de Almeida; Tzong-Luen Wang; Robert W Neumar; Lars W Andersen Journal: Resuscitation Date: 2020-03-03 Impact factor: 5.262
Authors: F Sanfilippo; C Corredor; C Santonocito; G Panarello; A Arcadipane; G Ristagno; T Pellis Journal: Resuscitation Date: 2016-08-03 Impact factor: 5.262
Authors: Gavin D Perkins; Claire Kenna; Chen Ji; Charles D Deakin; Jerry P Nolan; Tom Quinn; Charlotte Scomparin; Rachael Fothergill; Imogen Gunson; Helen Pocock; Nigel Rees; Lyndsey O'Shea; Judith Finn; Simon Gates; Ranjit Lall Journal: Intensive Care Med Date: 2020-01-07 Impact factor: 17.440